Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study | Zendy

Stéphanie Dominguez | Zendy; Jade Ghosn | Zendy; Gilles Peytavin | Zendy; Marguerite Guiguet | Zendy; Roland Tubiana | Zendy; M.A. Valantin | Zendy; Robert L. Murphy | Zendy; François Bricaire | Zendy; Y. Benhamou | Zendy; Christine Katlama | Zendy

Open Access

Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study

Author(s) -

Stéphanie Dominguez,

Jade Ghosn,

Gilles Peytavin,

Marguerite Guiguet,

Roland Tubiana,

M.A. Valantin,

Robert L. Murphy,

François Bricaire,

Y. Benhamou,

Christine Katlama

Publication year - 2010

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkq320

Subject(s) - cmin , efavirenz , medicine , abacavir , lopinavir , gastroenterology , reverse transcriptase inhibitor , regimen , nelfinavir , lamivudine , viral load , virology , sida , pharmacokinetics , viral disease , cmax , human immunodeficiency virus (hiv) , hepatitis b virus , virus , antiretroviral therapy

To compare plasma antiretroviral concentrations in HIV-HCV co-infected and in matched HIV mono-infected patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research